公开(公告)号：US20070218154A1

公开(公告)日：2007-09-20

申请号：US11404637

申请日：2006-02-13

Applicant: Mary Erranna Williams

Inventor： Mary Erranna Williams

IPC: A61K36/18

CPC classification number: A61K36/328 ,  A61K31/125 ,  A61K36/28 ,  A61K36/35 ,  A61K36/45 ,  A61K36/47 ,  A61K36/53 ,  A61K36/532 ,  A61K36/84 ,  A61K36/886 ,  A61K2300/00

Abstract: New Remedy is all natural remedy for the relief of muscle and joint pain. The mode of application has been basically the same since the beginning of time—using your hands to massage a site with or without something to relieve pain. However, this product is new, and made from what was put on earth for our benefit. It is the combination of herbs and emollients that give the relief when applied.

Abstract translation: 新的补救措施是减轻肌肉和关节疼痛的天然补救措施。 自开始以来，应用模式已经基本相同 - 使用双手按摩某些网站可以减轻疼痛或减轻疼痛。 然而，这种产品是新的，并且是由我们所用的东西制成的。 草药和润肤剂的组合在使用时给予缓解。

公开(公告)号：US07223423B2

公开(公告)日：2007-05-29

申请号：US11034995

申请日：2005-01-12

Applicant: Julie Y. Hwa

Inventor： Julie Y. Hwa

IPC: A61K36/00

CPC classification number: A61Q19/08 ,  A61K8/97 ,  A61K35/20 ,  A61K35/57 ,  A61K36/185 ,  A61K36/23 ,  A61K36/324 ,  A61K36/41 ,  A61K36/42 ,  A61K36/48 ,  A61K36/532 ,  A61K36/54 ,  A61K36/61 ,  A61K36/736 ,  A61K36/81 ,  A61K36/835 ,  A61K36/899 ,  A61Q7/00 ,  A61Q19/00 ,  A61Q19/02 ,  A61K2300/00

Abstract: A skin treatment composition, comprising an effective combination of ingredients selected from cumin, cloves, peach kernel, olibanum, eagle wood, giant hyssop, almond, and pachira macracarpa is provided. The composition can be used as a skin cleanser, as a deodorant, and to treat a wide array of skin problems, including signs of aging, such as wrinkles, and skin sagging, dark spots, skin infections, skin irritation, cuts, scarring, acne, cold sores, chapped lips, and varicose veins.

Abstract translation: 提供了一种皮肤治疗组合物，其包含选自孜然，丁香，桃仁，橄榄，鹰木，巨海索草，杏仁和马齿苋的成分的有效组合。 该组合物可用作皮肤清洁剂，作为除臭剂，并用于治疗各种皮肤问题，包括衰老迹象，如皱纹，皮肤下垂，黑斑，皮肤感染，皮肤刺激，切口，疤痕， 痤疮，感冒疮，裂口唇和静脉曲张。

公开(公告)号：US20040071792A1

公开(公告)日：2004-04-15

申请号：US10469025

申请日：2003-08-26

Inventor： Hyeong Kyu Lee ,  Sei Ryang Oh ,  Kyung Seop Ahn ,  Soon Ja Chol ,  Jung Hee Kim ,  Goo Taeg Oh ,  Jung Joo Hong ,  Seong Kyu Park ,  Woo Namkung

IPC: A61K035/78

CPC classification number: A61K36/532 ,  A23L33/105 ,  A23L33/11

Abstract: A composition of Agastache rugosa and tilianin obtained by separation-purification for anti-inflammation and anti-atherosclerosis, and more particularly, an extract of Agastache rugosa and tilianin odtained therefrom by separation-purification which are effective in preventing and treating not only inflammatory diseases but also atherosclerosis related to inflammatory responses and disease in the circulatory system caused by atherosclerosis because they are excellent in inhibiting the activity of complement systems as a factor of inflammatory responses, the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecular-1 (VCAM-1), and the production of nitric oxide (NO). They can also significantly reduce the development of atherosclerosis due to the inflammatory response.

Abstract translation: 通过用于抗炎和抗动脉粥样硬化的分离纯化获得的藿香粗提物和斜纹肌苷的组合物，更特别地，通过分离纯化从其中提取的藿香和，藜提取物，其有效预防和治疗不仅炎性疾病， 还涉及动脉粥样硬化与由动脉粥样硬化引起的循环系统中的炎症反应和疾病有关，因为它们作为炎症反应因子抑制补体系统的活性，细胞间粘附分子-1（ICAM-1）和血管细胞粘附的表达 分子-1（VCAM-1）和一氧化氮（NO）的产生。 它们还可以显着减少由于炎症反应引起的动脉粥样硬化的发展。

公开(公告)号：US20020025348A1

公开(公告)日：2002-02-28

申请号：US09875299

申请日：2001-06-05

Inventor： Amaresh Basu ,  Keith Hoffman

IPC: A61K035/78

CPC classification number: A61K36/718 ,  A61K36/48 ,  A61K36/532 ,  A61K36/57 ,  A61K36/575 ,  A61K36/63 ,  A61K36/736 ,  A61K36/752 ,  A61K36/756 ,  A61K36/9066 ,  A61K2300/00

Abstract: Compositions, including formulations, of plants for the treatment of Inflammatory Bowel Disease, Irritable Bowel Syndrome, and inflammatory and other related conditions, such as arthritis, are disclosed. The formulations consist of one or both of the two herbs Chen Pi (Citrus reticulata) and Wu Mei (Prunus mume), which, according to the invention, possess significant cytokine TNF-null inhibitory activity. The formulations also may include one or more of the following herbs which, according to the invention, inhibit PGE2: Hou Po (Magnoliae officinalis), Huang Bai (Phellodendron chinense), Huang Lian (Coptis chinensis), Huo Xiang (Agastaches rugosa), Pao Jiang (Zingiberis officinalis), Qin Pi (Fraxinus rynchophylla), and Zhi Gan Cao (Glycyrhizae inflata).

Abstract translation: 公开了用于治疗炎症性肠病，肠易激综合征以及炎症和其它相关病症如关节炎的植物的组合物，包括制剂。 制剂由两种草药陈皮（Citrus reticulata）和吴梅（Prunus mume）组成，根据本发明，它们具有显着的细胞因子TNF-α抑制活性。 制剂还可以包括一种或多种以下草药，根据本发明，本发明抑制PGE2：厚朴（Magnoliae officinalis），黄柏（黄柏），黄连（黄连），霍祥（藿香） ao Jiang in，（。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。

公开(公告)号：US06190685B1

公开(公告)日：2001-02-20

申请号：US09269270

申请日：1999-06-15

Applicant: Takeshi Karita

Inventor： Takeshi Karita

IPC: A61K970

CPC classification number: A61K9/0014 ,  A61K9/70 ,  A61K36/532 ,  A61K36/534 ,  A61K36/535 ,  A61K36/537 ,  A61K36/61 ,  A61K36/752 ,  A61K36/8962 ,  A61K47/06 ,  C07C259/06 ,  C09K15/34 ,  A61K2300/00

Abstract: An anti-oxidizing composition for scavenging free radicals, comprising at least one essential oil component containing a number of fat-soluble, low-molecular-weight compounds, a pharmaceutical composition comprising the above composition, and a process for preparing the same are described. Percutaneous absorption of the pharmaceutical composition is effective in treating immune diseases, particularly AIDS.

Abstract translation: 描述了一种用于清除自由基的抗氧化组合物，其包含至少一种含有多种脂溶性，低分子量化合物的精油组分，包含上述组合物的药物组合物及其制备方法。 药物组合物的经皮吸收对于治疗免疫疾病，特别是艾滋病是有效的。

公开(公告)号：US6121234A

公开(公告)日：2000-09-19

申请号：US19936

申请日：1998-02-06

Applicant: Leslie Z. Benet ,  Vincent J. Wacher ,  Reed M. Benet

Inventor： Leslie Z. Benet ,  Vincent J. Wacher ,  Reed M. Benet

IPC: A61K31/337 ,  A61K36/13 ,  A61K36/14 ,  A61K36/15 ,  A61K36/185 ,  A61K36/23 ,  A61K36/235 ,  A61K36/25 ,  A61K36/28 ,  A61K36/282 ,  A61K36/324 ,  A61K36/328 ,  A61K36/45 ,  A61K36/48 ,  A61K36/53 ,  A61K36/532 ,  A61K36/534 ,  A61K36/537 ,  A61K36/54 ,  A61K36/57 ,  A61K36/61 ,  A61K36/63 ,  A61K36/67 ,  A61K36/738 ,  A61K36/80 ,  A61K36/8962 ,  A61K36/898 ,  A61K36/899 ,  A61K36/9064 ,  A61K36/9068 ,  A61K38/13 ,  A61K47/10 ,  A61K47/44 ,  A61K31/12

CPC classification number: A61K47/44 ,  A61K31/337 ,  A61K36/13 ,  A61K36/14 ,  A61K36/15 ,  A61K36/185 ,  A61K36/23 ,  A61K36/235 ,  A61K36/25 ,  A61K36/28 ,  A61K36/282 ,  A61K36/324 ,  A61K36/328 ,  A61K36/45 ,  A61K36/48 ,  A61K36/53 ,  A61K36/532 ,  A61K36/534 ,  A61K36/537 ,  A61K36/54 ,  A61K36/57 ,  A61K36/61 ,  A61K36/63 ,  A61K36/67 ,  A61K36/738 ,  A61K36/752 ,  A61K36/80 ,  A61K36/8962 ,  A61K36/898 ,  A61K36/899 ,  A61K36/9064 ,  A61K36/9068 ,  A61K38/13 ,  A61K47/10 ,  Y10S514/946

Abstract: A method for increasing bioavailability and reducing inter- and intra-individual variability of an orally administered hydrophobic pharmaceutical compound, which comprises orally coadministering the pharmaceutical compound to a mammal in need of treatment with the compound with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration of 0.01 wt. % or less in an assay that measures conversion of cyclosporine to hydroxylated products using an assay system containing 250 .mu.g rat liver microsomes, 1 .mu.M cyclosporine, and 1 mM reduced nicotinamide adenine dinucleotide phosphate (NADPH) in 1 ml of 0.1 M sodium phosphate buffer, pH 7.4.

Abstract translation: 一种用于提高口服给药的疏水性药物化合物的生物利用度和降低个体间和个体间变异性的方法，其包括将药物化合物口服加入需要用化合物处理的哺乳动物，其中精油或精油成分的量为 足以在不存在精油或精油成分的情况下提供大于化合物的生物利用度的精油或精油成分存在下化合物的生物利用度，其中精油或精油成分至少具有活性 浓度为0.01重量％时抑制10％ 在使用含有250μg大鼠肝微粒体，1μM环孢菌素和1mM还原型烟酰胺腺嘌呤二核苷酸磷酸酯（NADPH）的测定系统测量环孢菌素至羟基化产物的1％的0.1M磷酸钠 缓冲液，pH 7.4。

公开(公告)号：US5916566A

公开(公告)日：1999-06-29

申请号：US973593

申请日：1998-02-11

Applicant: Leslie Z. Benet ,  Vincent J. Wacher ,  Reed M. Benet

Inventor： Leslie Z. Benet ,  Vincent J. Wacher ,  Reed M. Benet

IPC: A61K9/00 ,  A61K31/337 ,  A61K36/13 ,  A61K36/14 ,  A61K36/15 ,  A61K36/185 ,  A61K36/23 ,  A61K36/235 ,  A61K36/25 ,  A61K36/28 ,  A61K36/282 ,  A61K36/324 ,  A61K36/328 ,  A61K36/45 ,  A61K36/48 ,  A61K36/53 ,  A61K36/532 ,  A61K36/534 ,  A61K36/537 ,  A61K36/54 ,  A61K36/57 ,  A61K36/61 ,  A61K36/63 ,  A61K36/67 ,  A61K36/738 ,  A61K36/80 ,  A61K36/8962 ,  A61K36/898 ,  A61K36/899 ,  A61K36/9064 ,  A61K36/9068 ,  A61K38/00 ,  A61K38/13 ,  A61K47/10 ,  A61K47/44 ,  A61K35/78 ,  A61K31/335

CPC classification number: A61K47/44 ,  A61K31/337 ,  A61K36/13 ,  A61K36/14 ,  A61K36/15 ,  A61K36/185 ,  A61K36/23 ,  A61K36/235 ,  A61K36/25 ,  A61K36/28 ,  A61K36/282 ,  A61K36/324 ,  A61K36/328 ,  A61K36/45 ,  A61K36/48 ,  A61K36/53 ,  A61K36/532 ,  A61K36/534 ,  A61K36/537 ,  A61K36/54 ,  A61K36/57 ,  A61K36/61 ,  A61K36/63 ,  A61K36/67 ,  A61K36/738 ,  A61K36/752 ,  A61K36/80 ,  A61K36/8962 ,  A61K36/898 ,  A61K36/899 ,  A61K36/9064 ,  A61K36/9068 ,  A61K38/13 ,  A61K47/10 ,  A61K9/0014

Abstract: A method for increasing bioavailabilty of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration 0.01 wt. % or less in an assay that measures reduced conversion of cyclosporine to hydroxylated products using an assay system containing 250 .mu.g rat liver microsomes, 1 .mu.M cyclosporine, and 1 .mu.M reduced nicotinamide adenine dinucleotide phosphate (NADPH) in 1 ml of 0.1 M sodium phosphate buffer, pH 7.4.

Abstract translation: PCT No.PCT / US96 / 09607 Sec。 371日期1998年2月11日 102（e）1998年2月11日PCT PCT 1996年6月7日PCT公布。 出版物WO96 / 40192 日期：1996年12月19日一种增加口服给药的疏水性药物化合物的生物利用度的方法，其包括将药物化合物口服给予需要与精油或精油成分同时处理的哺乳动物，其量足以提供 在精油或精油成分存在下化合物的生物利用度大于化合物在不存在精油或精油成分时的生物利用度，其中精油或精油成分具有至少10％的抑制活性 浓度为0.01wt。 在使用含有250μg大鼠肝微粒体，1μM环孢菌素和1μM还原型烟酰胺腺嘌呤二核苷酸磷酸（NADPH）的测定系统测量环孢菌素至羟基化产物的转化率的测定中，％或更少，在1ml 0.1M 磷酸钠缓冲液，pH 7.4。

公开(公告)号：US5776462A

公开(公告)日：1998-07-07

申请号：US761321

申请日：1996-12-10

Applicant: Hsiu-Hsien Tsai ,  Shie-Ming Hwang

Inventor： Hsiu-Hsien Tsai ,  Shie-Ming Hwang

IPC: A61K9/20 ,  A61K9/68 ,  A61K36/53 ,  A61K36/532 ,  A61K47/00 ,  A61P11/04 ,  A61P31/04 ,  A61K35/78

CPC classification number: A61K36/53 ,  A61K36/532 ,  Y10S514/888

Abstract: The attachment of H. influenzae to human cells such as oropharyngeal cells, is inhibited by aqueous extracts of the plants known as Pogostemon cablin and Agastache rugosa. The composition obtained from the aqueous extraction of the plants Pogostemon cablin, Agastache rugosa or mixtures thereof is also effective in preventing or treating Otitis media and sore throat. The plant extract may be contained in a liquid enteral product such as an infant formula or may be incorporated into lozenges, candies, chewing gums and the like. The plant extract may also be administered as a throat spray or nasally using drops or a spray. A process for the production of a medicinal product is also disclosed.

Abstract translation: 流感嗜血杆菌对人细胞如口咽细胞的附着被称为Pogostemon cablin和Agastache rugosa的植物的水提取物抑制。 从植物Pogostemon cablin，藿香或其混合物的水提取物获得的组合物也可有效预防或治疗中耳炎和喉咙痛。 植物提取物可以包含在液体肠内产品如婴儿配方奶粉中，或者可以掺入锭剂，糖果，口香糖等中。 植物提取物也可以使用滴剂或喷雾剂作为咽喉喷雾剂或鼻腔给药。 还公开了用于生产药用产品的方法。

公开(公告)号：US5384123A

公开(公告)日：1995-01-24

申请号：US86863

申请日：1993-07-07

Applicant: Albert Metsada

Inventor： Albert Metsada

IPC: A61K8/92 ,  A61K8/97 ,  A61K36/00 ,  A61K36/16 ,  A61K36/185 ,  A61K36/28 ,  A61K36/45 ,  A61K36/53 ,  A61K36/532 ,  A61K36/537 ,  A61K36/67 ,  A61Q19/08 ,  A61K35/78 ,  C07G17/00

CPC classification number: A61Q19/08 ,  A61K36/16 ,  A61K36/185 ,  A61K36/28 ,  A61K36/45 ,  A61K36/53 ,  A61K36/532 ,  A61K36/537 ,  A61K36/67 ,  A61K8/922 ,  A61K8/97 ,  Y10S514/929

Abstract: The invention provides a topical composition for rejuvenating skin texture, comprising a first topically applicable component for stimulating the flow of blood in the arteries leading to, and capillaries feeding the muscles adjacent the skin; and a second topically applicable component for stimulating the flow of blood in the capillaries adjacent skin cells.

Abstract translation: 本发明提供了一种用于恢复皮肤纹理的局部组合物，其包括用于刺激通向导管的血液流动的第一局部适用组分，以及向皮肤附近喂养肌肉的毛细血管; 以及用于刺激邻近皮肤细胞的毛细血管中的血液流动的第二局部应用组分。